1. Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis

   • Patrick Vermersch
   • Jane Shanahan
   • Sven Schippling

   Commentary Open access 20 November 2019 Pages: 1 - 10

2. Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know

   • Mohamed AlJumah
   • Mona Marwan Alkhawajah
   • Peter Rieckmann

   Review Open access 13 February 2020 Pages: 11 - 23

   

3. Current Directions in Deep Brain Stimulation for Parkinson’s Disease—Directing Current to Maximize Clinical Benefit

   • Aristide Merola
   • Alberto Romagnolo
   • Leo Verhagen

   Review Open access 09 March 2020 Pages: 25 - 41

   

4. The Misdiagnosis of CIDP: A Review

   • Jeffrey A. Allen

   Review Open access 26 March 2020 Pages: 43 - 54

5. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review

   • Isa Ahmed AlSharoqi
   • Mohamed Aljumah
   • Per Soelberg Sørensen

   Review Open access 15 April 2020 Pages: 55 - 66

   

6. Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany

   • Sabrina Müller
   • Tobias Heidler
   • Thomas Wilke

   Original Research Open access 12 December 2019 Pages: 67 - 83

   

7. A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis

   • Michelle Allan
   • Lindsay Grant

   Original Research Open access 13 December 2019 Pages: 85 - 92

   

8. Care Among Migraine Patients in a Commercially Insured Population

   • Machaon Bonafede
   • Donna McMorrow
   • Stephen Silberstein

   Original Research Open access 15 February 2020 Pages: 93 - 103

   

9. Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years

   • Giampaolo Merlini
   • Teresa Coelho
   • Ben Ebede

   Original Research Open access 27 February 2020 Pages: 105 - 115

   

10. Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions

    • Koji Makino
    • Neil Mahant
    • Lara Aghajanian

    Original Research Open access 12 March 2020 Pages: 117 - 133

    

11. Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy

    • Alejandra González‐Duarte
    • Isabel Conceição
    • Michelle Stewart

    Original Research Open access 31 March 2020 Pages: 135 - 149

    

12. Potentially Inappropriate Medications in a Psychogeriatric Inpatient Ward: An Audit Based on Beers Criteria

    • Isabelle Moebs
    • Esther Abeln
    • Yoram Barak

    Original Research Open access 17 April 2020 Pages: 151 - 157

13. Pathway Analysis for Plasma β-Amyloid, Tau and Neurofilament Light (ATN) in World Trade Center Responders at Midlife

    • Minos Kritikos
    • Sean A. P. Clouston
    • Benjamin J. Luft

    Original Research Open access 30 April 2020 Pages: 159 - 171

    

14. Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing–Remitting Multiple Sclerosis: Quantifying the Patient’s Perspective

    • José Meca-Lallana
    • Jorge Maurino
    • Javier Ballesteros

    Brief Report Open access 18 January 2020 Pages: 173 - 179

    

15. Tardive Reactivation of Progressive Multiple Sclerosis During Treatment with Biotin

    • Alexis Demas
    • Jean-Philippe Cochin
    • Pierre Labauge

    Case Report Open access 19 December 2019 Pages: 181 - 185

    

16. A Case Report of Myoclonus-Dystonia with Isolated Myoclonus Phenotype and Novel Mutation Successfully Treated with Deep Brain Stimulation

    • Valentina Besa Lehmann
    • Marc Rosenbaum
    • Leo Verhagen Metman

    Case Report Open access 09 April 2020 Pages: 187 - 191

17. Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII Trials

    • Angelo Ghezzi
    • Tanuja Chitnis
    • Daniela Pohl

    Correction Open access 14 February 2020 Pages: 193 - 195